ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2822

Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women

Jeffrey Sparks1, Susan Malspeis 1, Jill Hahn 2, Andrea Roberts 2, Laura Kubzansky 2 and Karen Costenbader 1, 1Brigham and Women's Hospital, Boston, MA, 2Harvard School of Public Health, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: depression, Epidemiologic methods, prevention and mental health, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T109: Epidemiology & Public Health III: RA (2822–2827)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between depression and subsequent risk for developing RA is less clear. Therefore, we hypothesized that depression may increase RA risk. Since depression may develop in the period prior to clinical RA diagnosis, we decreased the potential for reverse causation by including a time separation between the assessment of depression and RA risk window.

Methods: We performed a prospective cohort study investigating depression and incident RA. We pooled data from the Nurses’ Health Study (NHS, 1992-2014) and NHSII (1993-2015). As in previous studies, depression was defined using a composite definition: report of clinician diagnosis, regular antidepressant use, or Mental Health Inventory-5 score < 60. Women reported RA diagnosis and 2 rheumatologists performed medical record review to confirm diagnosis using objective criteria and identify the date of diagnosis and serologic phenotype (seropositive: RF+ or CCP+). All incident RA cases met 1987 ACR or 2010 ACR/EULAR criteria. Measures of depression and covariates including smoking, body mass index, dietary quality, physical activity, and menopausal factors were obtained using biennial questionnaires. Cox regression estimated HRs and 95%CIs for RA (overall and by serologic phenotype) according to depression status, adjusted for potential confounders. All analyses included a lag that separated depression status and the window for RA risk by at least 4 years to lower the possibility that depressive symptoms preceding RA diagnosis explained the results.

Results: We analyzed n=194,700 women; mean age at baseline of 46.8 (SD 11.5) years and 24% of women had depression. A total of 834 incident RA cases (64% seropositive) occurred during 2,994,244 person-years of follow-up. In the age-adjusted analysis, women with depression had HR for all RA of 1.41 (95%CI 1.22-1.64, Table). After adjusting for covariates, the HR for all RA was attenuated, but still showed a modest but significant association (multivariable HR 1.28, 95%CI 1.28, 95%CI 1.10-1.49). After adjustment for covariates, depression was not statistically associated with seropositive RA (multivariable HR 1.10, 95%CI 0.91-1.32). However, depression was strongly associated with risk for incident seronegative RA (multivariable HR 1.70, 95%CI 1.32-2.19), independent of potential confounders including smoking, dietary intake, body mass index, physical activity, and menopause.

Conclusion: In this large prospective study, depression was associated with increased risk for incident RA, using stringent methods for RA case identification. The association of depressive symptoms with seronegative RA was not explained by measured lifestyle factors. We accounted for potential reverse causation of early RA symptoms leading to depression. Future studies are needed to replicate these findings and to elucidate potential mechanisms linking depression and seronegative RA, such as systemic inflammation or aberrant pain sensitivity.

Table. Hazard ratios for incident rheumatoid arthritis according to presence or absence of depression* among women in the Nurses’ Health Studies -n=194,700-, lagged by two questionnaire cycles -at least 4 years between depression and rheumatoid arthritis diagnosis assessments-.


Disclosure: J. Sparks, None; S. Malspeis, None; J. Hahn, None; A. Roberts, None; L. Kubzansky, None; K. Costenbader, Astra-Zeneca, 2, Glaxo Smith Kline, 2, Janssen Scientific Affairs, LLC, 2, Lupus Foundation of America, 2, Lupus Research Alliance, 2, Merck, 2.

To cite this abstract in AMA style:

Sparks J, Malspeis S, Hahn J, Roberts A, Kubzansky L, Costenbader K. Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/depression-and-subsequent-risk-for-incident-seronegative-rheumatoid-arthritis-among-women/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-and-subsequent-risk-for-incident-seronegative-rheumatoid-arthritis-among-women/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology